TrialHaematologica2015

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

Alessandro M Vannucchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.